Researcher
Chantal Mathieu
- Disciplines:Endocrinology and metabolic diseases
Affiliations
- Clinical and Experimental Endocrinology (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 75
- Continuous glucose monitoring for women with gestational diabetes: a randomized controlled trial: the CORDELIA studyFrom1 Jan 2024 → 29 Mar 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- European action for the Diagnosis of Early Non-clinical Type 1 diabetes For disease InterceptionFrom1 Nov 2023 → TodayFunding: Horizon Europe - Digital, Industry and Space
- Quality of diabetes care: the role of health dataFrom29 Mar 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Neutrophils: neglected as potential players in autoimmune type 1 diabetes initiation, progression, and perpetuationFrom1 Jan 2023 → TodayFunding: FWO research project (including WEAVE projects)
- Unique IsoPlexis technology for multiplexed single cell functional profilingFrom1 Jan 2023 → TodayFunding: BOF - scientific equipment program
- Innovative strategies for screening, diagnosis and prevention of type 1 diabetes.From13 Dec 2022 → 15 Dec 2022Funding: BOF - various
- "SyneRegIm": exploring the SYNErgistic effect of β-cell REGeneration and emerging IMmune intervention strategies to prevent and/or reverse type 1 diabetesFrom1 Sep 2022 → TodayFunding: Foreign private sponsor - undefined
- The SERENA study: Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes: a double blind RCTFrom30 Aug 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Characterization of the dynamic immunophenotype during type 1 diabetes progression to identify predictive biomarkers of anti-CD3 mono- and combination therapy in disease prevention and reversal in miceFrom7 Aug 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
Publications
561 - 570 of 708
- The importance of glycemic control: how low should we go with HbA1c? Start early, go safe, go low(2011)
Authors: Katrien Fouzia Benhalima, Chantal Mathieu
Pages: 202 - 207 - Immune and cell therapy in type 1 diabetes: too little too late?(2011)
Authors: Pieter Gillard, Chantal Mathieu
Pages: 609 - 21 - Vitamin D and the Immune system: getting it right(2011)
Authors: Chantal Mathieu
Pages: 178 - 186 - Two-dimensional gel proteome reference map of INS-1E cells(2011)
Authors: Wannes D'Hertog, Michael Maris, Lieven Thorrez, Etienne Waelkens, Lut Overbergh, Chantal Mathieu
Pages: 1365 - 1369 - 1,25-Dihydroxyvitamin D(3) and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer(2011)
Authors: Isabelle Clinckspoor, Lieve Verlinden, Lut Overbergh, Roger Bouillon, Chantal Mathieu, Mieke Verstuyf, Brigitte Decallonne
Pages: 1 - 9 - Degludec insulin, insuline ultra long of new generation, used once a day or 3 times per week in patients with type 2 diabetes: comparison with insulin Glargine(2011)
Authors: D Raccah, A Penfornis, D Huet, P Valensi, B Zinman, G Fulcher, P Rao, N Thomas, L Endhal, T Johansen, et al.
Pages: A5 - A5 - 1,25-Dihydroxyvitamin D(3) and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer(2011)
Authors: Isabelle Clinckspoor, Lieve Verlinden, Lut Overbergh, C Korch, Roger Bouillon, Chantal Mathieu, Mieke Verstuyf, Brigitte Decallonne
Pages: 1 - 9 - Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial(2011)
Authors: Chantal Mathieu
Pages: 924 - 31 - Pdx1- and Ngn3-Cre-mediated PLAG1 expression in the pancreas leads to endocrine hormone imbalances that affect glucose metabolism(2011)
Authors: Jeroen Declercq, Conny Gysemans, Anica Schraenen, Katleen Lemaire, Frans Schuit, Chantal Mathieu, Nadine Ectors, Wim Van de Ven, Catherine Verfaillie
Pages: 1285 - 1297 - Sensor-augmented pump therapy lowers HbA(1c) in suboptimally controlled Type 1 diabetes; a randomized controlled trial(2011)
Authors: Chantal Mathieu
Pages: 1158 - 1167
Patents
1 - 6 of 6
- Biomarkers for diabetes therapy (Inventor)
- Biomarkers for diabetes therapy (Inventor)
- Improved methods for pancreatic islet transplantation (Inventor)
- Citrullinated peptides for diagnosis or treatment of diabetes (Inventor)
- Improved methods for pancreatic islet transplantation (Inventor)
- RESISTANCE TO OXIDATIVE STRESS (Inventor)